Results 11 to 20 of about 18,115 (178)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer [PDF]

Frontiers in Pharmacology, 2023
Introduction: Colorectal cancer is one of the most prevalent life-threatening malignant tumors with high incidence and mortality. However, the efficacy of current therapeutic regimens is very limited.
Tao Yuan, Ruilin Wu, Weihua Wang, Yue Liu, Wencheng Kong, Bo Yang, Qiaojun He, Qiaojun He, Qiaojun He, Hong Zhu, Hong Zhu, Hong Zhu   +11 more
doaj   +2 more sources

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation

Pharmaceutics, 2021
This study was performed to evaluate the interaction between conventional or high-dose radiotherapy (RT) and the pharmacokinetics (PK) of regorafenib in concurrent or sequential regimens for the treatment of hepatocellular carcinoma.
Tung-Hu Tsai, Yu-Jen Chen, Li-Ying Wang, Chen-Hsi Hsieh   +3 more
doaj   +2 more sources

Regorafenib promotes antitumor progression in melanoma by reducing RRM2

iScience
Summary: Melanoma is a malignant tumor with a terrible prognosis. Although so many therapies are used for melanoma, the overall survival rate is still poor globally. Novel therapies are still required.
Xiuyun Xuan, Yanqiu Li, Changzheng Huang, Yong Zhang   +3 more
doaj   +2 more sources

Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer [PDF]

Cancer Management and Research
Jiayun Zhong,1 Yu Liu,2 Qian Fu,1 Dan Huang,2 Wenjun Gong,2 Jian Zou2 1Department of Pharmaceutical, the People’s Hospital of Pengzhou, Chengdu, Sichuan, 611930, People’s Republic of China; 2Department of Clinical Pharmacy, the People’s Hospital of ...
Zhong J, Liu Y, Fu Q, Huang D, Gong W, Zou J   +5 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Characterization of Glioblastoma Cells Response to Regorafenib [PDF]

, 2022
Glioblastoma (GBM), the most malignant primary brain tumor in adults. Although not frequent, it has a relevant social impact because the peak incidence coincides with the age of professional maturity.
Chiesa S., Pallini R., D'Alessandris Q. G., Formato A.   +3 more
core   +2 more sources

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients [PDF]

, 2021
BACKGROUND Genetic variants in the CCL5/CCR5 pathway have been shown to predict regorafenib efficacy in patients with metastatic colorectal cancer (mCRC). This study investigated the biological role of CCL4 and CCL3 gene polymorphisms in patients with
WU ZHANG, Schirripa, Marta, AFSANEH BARZI, Cao, Shu, SHU CAO, Okazaki, Satoshi, Suenaga, Mitsukuni, MITSUKUNI SUENAGA, Zhang, W U, Miyamoto, Yuji, Barzi, Afsaneh, Lenz, Heinz-Josef, TETSUO MASHIMA, SATOSHI OKAZAKI, HEINZ-JOSEF LENZ, Mashima, Tetsuo, MARTIN D. BERGER, Yamaguchi, Toshiharu, MARTA SCHIRRIPA, YUJI MIYAMOTO, Berger, Martin D., TOSHIHARU YAMAGUCHI   +21 more
core   +1 more source

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Frontiers in Oncology, 2020
Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance.
Weiwei Shi, Weiwei Shi, Shan Zhang, Shan Zhang, Ding Ma, Ding Ma, Dongliang Yan, Guang Zhang, Guang Zhang, Guang Zhang, Yin Cao, Yin Cao, Yin Cao, Zhongxia Wang, Zhongxia Wang, Zhongxia Wang, Junhua Wu, Chunping Jiang, Chunping Jiang, Chunping Jiang   +19 more
doaj   +1 more source

Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway. [PDF]

PLoS ONE, 2017
Regorafenib is an oral small-molecule multi kinase inhibitor. Recently, several clinical trials have revealed that regorafenib has an anti-tumor activity in gastric cancer.
Xiao-Lin Lin, Qi Xu, Lei Tang, Li Sun, Ting Han, Li-Wei Wang, Xiu-Ying Xiao   +6 more
doaj   +1 more source